These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16250642)

  • 21. A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARS-CoV 3C-like peptidase.
    Yin J; Niu C; Cherney MM; Zhang J; Huitema C; Eltis LD; Vederas JC; James MN
    J Mol Biol; 2007 Aug; 371(4):1060-74. PubMed ID: 17599357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris.
    Nguyen TT; Woo HJ; Kang HK; Nguyen VD; Kim YM; Kim DW; Ahn SA; Xia Y; Kim D
    Biotechnol Lett; 2012 May; 34(5):831-8. PubMed ID: 22350287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Profiling of substrate-specificity and rational design of broad-spectrum peptidomimetic inhibitors for main proteases of coronaviruses.
    Chuck CP; Ke ZH; Chen C; Wan DC; Chow HF; Wong KB
    Hong Kong Med J; 2014 Aug; 20 Suppl 4():22-5. PubMed ID: 25224114
    [No Abstract]   [Full Text] [Related]  

  • 24. Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.
    Zhou L; Liu Y; Zhang W; Wei P; Huang C; Pei J; Yuan Y; Lai L
    J Med Chem; 2006 Jun; 49(12):3440-3. PubMed ID: 16759084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of the maturation process of SARS-CoV 3CL protease.
    Hsu MF; Kuo CJ; Chang KT; Chang HC; Chou CC; Ko TP; Shr HL; Chang GG; Wang AH; Liang PH
    J Biol Chem; 2005 Sep; 280(35):31257-66. PubMed ID: 15788388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety.
    Konno S; Thanigaimalai P; Yamamoto T; Nakada K; Kakiuchi R; Takayama K; Yamazaki Y; Yakushiji F; Akaji K; Kiso Y; Kawasaki Y; Chen SE; Freire E; Hayashi Y
    Bioorg Med Chem; 2013 Jan; 21(2):412-24. PubMed ID: 23245752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease.
    Konno H; Wakabayashi M; Takanuma D; Saito Y; Akaji K
    Bioorg Med Chem; 2016 Mar; 24(6):1241-54. PubMed ID: 26879854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation.
    Nguyen TT; Ryu HJ; Lee SH; Hwang S; Breton V; Rhee JH; Kim D
    Bioorg Med Chem Lett; 2011 May; 21(10):3088-91. PubMed ID: 21470860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic inhibitor binding to the papain-like protease of human SARS coronavirus: mechanistic and inhibitor design implications.
    Lee H; Cao S; Hevener KE; Truong L; Gatuz JL; Patel K; Ghosh AK; Johnson ME
    ChemMedChem; 2013 Aug; 8(8):1361-72. PubMed ID: 23788528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features.
    Chen L; Li J; Luo C; Liu H; Xu W; Chen G; Liew OW; Zhu W; Puah CM; Shen X; Jiang H
    Bioorg Med Chem; 2006 Dec; 14(24):8295-306. PubMed ID: 17046271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of homology modeling of the severe acute respiratory syndrome (SARS) coronavirus main protease for structure based drug design.
    Takeda-Shitaka M; Nojima H; Takaya D; Kanou K; Iwadate M; Umeyama H
    Chem Pharm Bull (Tokyo); 2004 May; 52(5):643-5. PubMed ID: 15133227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a red-shifted fluorescence-based assay for SARS-coronavirus 3CL protease: identification of a novel class of anti-SARS agents from the tropical marine sponge Axinella corrugata.
    Hamill P; Hudson D; Kao RY; Chow P; Raj M; Xu H; Richer MJ; Jean F
    Biol Chem; 2006 Aug; 387(8):1063-74. PubMed ID: 16895476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies.
    Thanigaimalai P; Konno S; Yamamoto T; Koiwai Y; Taguchi A; Takayama K; Yakushiji F; Akaji K; Chen SE; Naser-Tavakolian A; Schön A; Freire E; Hayashi Y
    Eur J Med Chem; 2013 Oct; 68():372-84. PubMed ID: 23994330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A structural view of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters.
    Verschueren KH; Pumpor K; Anemüller S; Chen S; Mesters JR; Hilgenfeld R
    Chem Biol; 2008 Jun; 15(6):597-606. PubMed ID: 18559270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study.
    Thanigaimalai P; Konno S; Yamamoto T; Koiwai Y; Taguchi A; Takayama K; Yakushiji F; Akaji K; Kiso Y; Kawasaki Y; Chen SE; Naser-Tavakolian A; Schön A; Freire E; Hayashi Y
    Eur J Med Chem; 2013 Jul; 65():436-47. PubMed ID: 23747811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase.
    Lai L; Han X; Chen H; Wei P; Huang C; Liu S; Fan K; Zhou L; Liu Z; Pei J; Liu Y
    Curr Pharm Des; 2006; 12(35):4555-64. PubMed ID: 17168761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease.
    Ren Z; Yan L; Zhang N; Guo Y; Yang C; Lou Z; Rao Z
    Protein Cell; 2013 Apr; 4(4):248-50. PubMed ID: 23549610
    [No Abstract]   [Full Text] [Related]  

  • 38. Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus.
    Chou CY; Chien CH; Han YS; Prebanda MT; Hsieh HP; Turk B; Chang GG; Chen X
    Biochem Pharmacol; 2008 Apr; 75(8):1601-9. PubMed ID: 18313035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication.
    Ratia K; Pegan S; Takayama J; Sleeman K; Coughlin M; Baliji S; Chaudhuri R; Fu W; Prabhakar BS; Johnson ME; Baker SC; Ghosh AK; Mesecar AD
    Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16119-24. PubMed ID: 18852458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe acute respiratory syndrome coronavirus 3C-like proteinase N terminus is indispensable for proteolytic activity but not for enzyme dimerization. Biochemical and thermodynamic investigation in conjunction with molecular dynamics simulations.
    Chen S; Chen L; Tan J; Chen J; Du L; Sun T; Shen J; Chen K; Jiang H; Shen X
    J Biol Chem; 2005 Jan; 280(1):164-73. PubMed ID: 15507456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.